In the Phase III GIMEMA ALL2820 trial, presented at ASH, 94 percent of patients who received the chemo-free regimen had a ...

In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

One study found frail patients tend to have worse survival outcomes on the therapy, but another challenged the idea that ...

In a large analysis presented at ASH's annual meeting, researchers reported that patients' MRD status after intensive chemo can predict their survival.

The results mark a setback for the hypothesis that drugs like semaglutide could provide a neuroprotective effect for patients ...

The Phase III trial, testing the drug in patients whose cancers are Philadelphia chromosome-positive, will expand to the US and Europe.

The firm is developing Lumevoq as a treatment for Leber hereditary optic neuropathy caused by mutations in the ND4 mitochondrial gene.

AACR held an event on Capitol Hill with the NCI director and a legislator to discuss government efforts to support pediatric cancer research.

The agency approved the autologous CAR T-cell therapy based on data showing that around 62 percent of patients had no signs of cancer after a single infusion.

Trontinemab, designed to reach the brain better than gantenerumab, led to amyloid negativity in 92 percent of patients at the ...

The nonprofit is focused on access to precision medicine testing and treatment for former Special Operations Forces personnel ...